Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MedMira Inc V.MIR

Alternate Symbol(s):  MMIRF

Healthcare Medical Devices
MedMira Inc. is a Canada-based developer and manufacturer of Rapid Vertical Flow (RVF) diagnostics. The Company's tests provide hospitals, labs, clinics and individuals with instant disease diagnosis, such as human immunodeficiency virus (HIV), syphilis, hepatitis, and SARS-CoV-2, in three steps. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. Its research is focused on specific areas of the broader diagnostics market, namely the rapid, point-of-care, and in vitro sectors. Its tests are sold globally under the REVEAL, REVEALCOVID-19, Multiplo and Miriad brands. Based on its patented Rapid Vertical Flow Technology, the Company's rapid HIV test has regulatory approvals in Canada, the United States, China and the European Union. Its manufacturing facilities are located in Halifax, Nova Scotia, Canada. It provides access to its RVF Technology for researchers, developers, and biotech companies on a license basis.


TSXV:MIR - Post by User

MedMira Inc > More Active on LinkedIn
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by BlankChexon Jul 22, 2021 7:59pm
123 Views
Post# 33594367

RE:RE:More Active on LinkedIn

RE:RE:More Active on LinkedInhttps://www.linkedin.com/posts/medmira-inc-_this-is-just-one-of-our-many-customer-feedbacks-activity-6823627255282061312-8xiW

This is just one of our many customer feedbacks (this is from Germany, Starnberg):

"Ich kann nur immer wieder berichten, da der REVEALCOVID-Test bei uns in der Praxis super funktioniert : Testergebnis in 2 min - viele positive Tests 6-8 Wochen nach der COVID19-Impfung.

Alle Patienten kommen in 3 Monaten wieder, damit Sie wissen, ob Sie sich im Herbst noch einmal sich impfen lassen mssen.

Facit: wir bentigen in Deutschland & auch in Europa den REVEALCOVID-Test fr die nchste „COVID-Welle“ & vor der nchsten Auffrischungsimpfung.
          Aufwndige quantitative Antikrper-Tests sind m.E. hierfr nicht notwendig."
 
 
This is just one of our many customer feedbacks (this is from Germany, Starnberg):

"I can only report again and again that the REVEALCOVID test works great in our practice: test result in 2 min - many positive tests 6-8 weeks after the COVID19 vaccination.

All patients will come back in 3 months so you know if you need to get vaccinated again in the fall.

Facit: we need the REVEALCOVID test in Germany & also in Europe for the next "COVID wave" & before the next booster vaccination.
          In my opinion, complex quantitative antibody tests are not necessary for this."

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities